In 2025, the European League Against Rheumatism(EULAR) and the European Respiratory Society(ERS) jointly released the first clinical practice guidelines for the management of connective tissue disease-associated interstitial lung disease (CTD-ILD), with a particular focus on systemic sclerosis-associated ILD(SSc-ILD). Based on evidence-based principles, the guidelines provide a comprehensive framework encompassing screening, progression assessment, therapeutic strategies, and follow-up. Notably, the guidelines emphasize the clinical value of combination therapy for patients at high risk or with rapidly progressive disease. This article summarizes and interprets the key recommendations, including HRCT-based screening, multi-dimensional assessment tools, stratified pharmacological strategies, classification of drug mechanisms, and risk-duration-based follow-up protocols. It aims to provide up-to-date international guidance for clinical decision-making and research in the management of SSc-ILD.

Systemic sclerosis (SSc) is a systemic autoimmune disease, characterized by skin fibrosis and multiple organ involvement. The etiology is currently largely unclear, and no curative therapies are available. In 2024, the treatment recommendation was updated by the European Alliance of Associations for Rheumatology (EULAR). The current paper aims to introduce and interpret this updated recommendation, and the evidence derived clinical studies, providing a reference for the clinical practice of SSc.

In 2025, the European League Against Rheumatism(EULAR) and the European Respiratory Society(ERS) jointly released the first clinical practice guidelines for the management of connective tissue disease-associated interstitial lung disease (CTD-ILD), with a particular focus on systemic sclerosis-associated ILD(SSc-ILD). Based on evidence-based principles, the guidelines provide a comprehensive framework encompassing screening, progression assessment, therapeutic strategies, and follow-up. Notably, the guidelines emphasize the clinical value of combination therapy for patients at high risk or with rapidly progressive disease. This article summarizes and interprets the key recommendations, including HRCT-based screening, multi-dimensional assessment tools, stratified pharmacological strategies, classification of drug mechanisms, and risk-duration-based follow-up protocols. It aims to provide up-to-date international guidance for clinical decision-making and research in the management of SSc-ILD.

Systemic sclerosis (SSc) is a systemic autoimmune disease, characterized by skin fibrosis and multiple organ involvement. The etiology is currently largely unclear, and no curative therapies are available. In 2024, the treatment recommendation was updated by the European Alliance of Associations for Rheumatology (EULAR). The current paper aims to introduce and interpret this updated recommendation, and the evidence derived clinical studies, providing a reference for the clinical practice of SSc.

Antibodies, Antinuclear ; Autoantibodies ; China ; Cohort Studies ; Humans ; Scleroderma, Systemic

OBJECTIVETo examine the association between the genotype (LL, LS and SS) of serotonin transporter promoter gene polymorphism(5-HTTLPR) and clinicopathological factors, and to investigate the effect of 5-HTTLPR on the prognosis of colorectal cancer patients.

METHODSData of peripheral blood samples of 161 colorectal cancer patients at the Second Affiliated Hospital of Guangzhou Medical University from October 2009 to January 2014 were collected retrospectively. The genotyping of 5-HTTLPR was determined by PCR and agarose gel electrophoresis. Coincidence Chi-square test was used to examine the 5-HTTLPR genotype with Hardy-Weinberg law. Chi-square test and Cox multifactor model were used to analyze the association of 5-HTTLPR genotype with clinicopathology and prognosis. All the patients were informed and agreed to participate in the study. This study was approved by the Hospital Ethics Committee (2015056).

RESULTSOf 161 colorectal cancer patients, 89 were male and 72 were female; the median age was 64 (25-85) years; 86 (53.5%) cases were colon cancer and 75 (46.5%) were rectal cancer. Genotype was LL in 12 cases, LS in 59 cases and SS in 90 cases, which complied with the law of Hardy-Weinberg genetic balance (χ²=0.288, P=0.592). Univariate analysis showed that 5-HTTLPR gene polymorphism was only associated with lymph node metastasis [lymph node metastasis rate: LL and LS genotype 21.1% (15/71);SS genotype 40.0% (36/90), χ²= 6.532, P=0.011]. The 3-year and 5-year overall survival rates of whole patients were 71% and 63% respectively. Multivariate analysis revealed that the SS genotype was an independent risk factor affecting the overall survival of colorectal cancer patients(HR=1.933, 95%CI:1.090-3.428, P=0.024).

CONCLUSIONAmong genotypes of 5-HTTLPR gene, colorectal cancer patients with SS genotype have higher risk of lymph node metastasis and poorer prognosis.

Adult ; Aged ; Aged, 80 and over ; Colorectal Neoplasms ; genetics ; pathology ; Female ; Genotype ; Humans ; Male ; Middle Aged ; Polymorphism, Genetic ; Prognosis ; Retrospective Studies ; Serotonin Plasma Membrane Transport Proteins ; genetics

Objective To analyze the impact of rs3826392 polymorphism in MKK4 promoter on prognosis of colorectal cancer cases (CRC) receiving adjuvant chemotherapy. Methods The associations between rs3826392 genotype of 203 CRC cases receiving adjuvant chemotherapy and clinicopathologic factors,overall survival (OS), disease free survival (DFS) were analyzed retrospectively. Results No association was found between rs3826392 genotype and clinicopathologic factors (P > 0.05). TG+GG genotype had better OS (P = 0.018) and DFS (P =0.019) when compared with TT genotype. Cox multivariate model showed rs3826392 TG+GG genotype remained independent favorable factor for OS(HR = 0.389;95%CI = 0.177-0.855) and DFS(HR=0.491;95%CI = 0.271-0.890) respectively. Conclusion -1304G variant genotypes (i.e., TG+GG) in rs3826392 may be the biomarker of better prognosis in CRC receiving adjuvant chemotherapy.

Objective To explore the correlation of anti-ganglioside antibodies with clinical features of systemic lupus erythematosus (SLE). Methods Samples of serum were collected from 48 patients with SLE. Three were male and 45 were female. Their average age was 33±12 (15～59). The serum anti-ganglioside antibodies of 10 patients with rheumatoid arthritis (RA), 4 with Sj(o)gren's syndrome (SS), 1 patient with mixed connective tissue disease (MCTD), 1 with polymyositis (PM), and 97 healthy controls(HC) were alsoexamined. Levels of anti-GM1-IgM/IgG, anti-GQ1b-IgM/IgG antibodies in the serum were examined by amodified ELISA. Anti-dsDNA-IgG antibody of SLE was tested according to the ELISA kit protocol. The associations of anti-GM1-IgM/IgG and anti-GQ1b-IgM/IgG antibodies with clinical features were analyzed. x2test, one-way ANOVA, Dunnett t-test were used for statistical analysis. Results By using modified ELISA,the upper limit of reference value of anti-GM1-IgM/IgG antibodies, anti -GQ1b-IgM/IgG antibodies in the serum of Chinese SLE patients were 0.411, 0.408, 0.481 and 0.441 res-pectively. 19% patients with SLE were sero-positive for anti-GM1 antibody, 4% for IgM antibody isotype and 15% for IgG antibody isotype. Anti-GM1-IgG antibody was significantly increased in the serum of patients with SLE (0.33±0.09), higher than that of the HC (0.27±0.05) (P<0.05), RA (0.29±0.08), SS(0.27±0.06), PM ( 0.288 ), but one of the MCTD( 0.423 ).There was no significant associations between anti-GM1-IgM/IgG, anti-GQ1b-IgM/IgG antibodies and NPSLE and anti-dsDNA-IgG antibody (P>0.05). Conclusion Peripheral autoimmune response against GM1 can be detected in SLE patients, and it may be involved in the pathogenesis of SLE. No association of antiGM1-IgM/IgG antibodies or anti-GQ1b-IgM/IgG antibodies with clinical features of SLE can be discovered.